Langer, Dr Salomón, Department of Pharmacology, Harvard Medical School, Boston, Massachusetts, USA / ARC Institute of Animal Physiology, Babraham, Cambridge / Institute of Pharmacological Investigations, Buenos Aires, Argentina / Department of Pharmacology, University of Colorado Medical Center, Denver, Colorado, USA / Laboratoires d'Etudes et de Recherches Synthelabo, Paris, France

Including re Langer's work at Harvard Medical School Department of Pharmacology with introductory reference; his Wellcome Research Fellowship to work in Babraham, including details of investigations on catecholamine release, arrangements for his arrival, accommodation and stipends, financial support for his family, grant extension; abstracts of his research at Babraham entitled 'The effects of phenolybenzamine on metabolism of H3-noradrenaline released from the isolated nictitating membrane', 'Release of H3-noradrenaline from the isolated nictitating membrane of the cat by intramural stimulation', 'Monoamine oxidase and catechol-o-methyl transferase activities in cat nictitating membrane and rat and guinea-pig vas deferens after surgical sympathectomy'; papers written jointly with Marthe Vogt; arrangements for Marthe Vogt's visit to Buenos Aires in 1970; Langer's appointment to Colorado and US immigration problems; references by Marthe Vogt in support of Langer's applications to the University of Sydney, Wellcome Research Laboratories in Beckenham and University of Toronto; Langer's nomination for the Albert Lasker Medical Research Award (with biography and summaries of his research work); seminars and symposia; Marthe Vogt's request for sample compound Progabide (SL 76002) from LERS (and refusal to sign the 'no publication without permission' clause imposed by the company)

Feb 1966-Jul 1983

1 file

Manuscripts and Archives online catalogue

This item is restricted. You will need to complete a Restricted Access form agreeing to anonymise personal data before you will be allowed to view this item. Please see our Access Policy for more details. Restricted until 1 January 2044.